Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.53 |
| ▸ | PPARG | P37231 | 6/20 | 0.53 |
| ▸ | CTSS | P25774 | 6/20 | 0.52 |
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4397406 | 1.00 | PPARA (0.53) | PPARAPPARGCTSSCTSKPTPN1 | |
| SCHEMBL27203762 | 0.91 | PPARA (0.53) | PPARAPPARGCTSSCTSKPTPN1 | |
| SCHEMBL27207446 | 0.91 | PPARA (0.53) | PPARAPPARGCTSSCTSKPTPN1 | |
| SCHEMBL4390584 | 0.90 | CTSS (0.48) | PPARAPPARGCTSSCTSKPTPN1 | |
| SCHEMBL3856557 | 0.90 | CTSS (0.48) | PPARAPPARGCTSSCTSKPTPN1 | |
| SCHEMBL4390581 | 0.90 | CTSS (0.48) | PPARAPPARGCTSSCTSKPTPN1 | |
| SCHEMBL30461851 | 0.87 | CTSS (0.55) | PPARAPPARGCTSSCTSKPTPN1 | |
| SCHEMBL5318364 | 0.87 | CTSS (0.55) | PPARAPPARGCTSSCTSKPTPN1 | |
| SCHEMBL5845049 | 0.87 | CTSS (0.55) | PPARAPPARGCTSSCTSKPTPN1 | |
| SCHEMBL5845045 | 0.87 | CTSS (0.55) | PPARAPPARGCTSSCTSKPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105473575-B | Benzimidazolyl-methylurea derivatives as ALX receptor agonists | 爱杜西亚药品有限公司 | 2017-11-24 | — | — | CN | disclosed |
| EP-3030560-B1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-06-21 | — | — | EP | disclosed |
| US-9663473-B2 | Benzimidazolyl-methyl urea derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-05-30 | — | — | US | disclosed |
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-07-14 | — | — | US | disclosed |
| EP-3030560-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd (CH) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015019325-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-02-12 | — | — | WO | disclosed |
| EP-1554256-B1 | PIPERIDINO PYRIMIDINE DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO INC (US) | 2009-12-09 | — | — | EP | disclosed |
| US-7307164-B2 | β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1490335-B1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1583534-A4 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2007-08-29 | — | — | EP | disclosed |
| US-7208498-B2 | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK & CO., INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060052382-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. | 2006-03-09 | — | — | US | disclosed |
| US-20060040963-A1 | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| EP-1583534-A1 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050107390-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. | 2005-05-19 | — | — | US | disclosed |
| WO-2004058266-A1 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107390-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | PPARA 986/4885PPARG 961/4885CTSS 702/4885 |
| US-20060052382-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | PPARA 367/4885PPARG 563/4885CTSS 1879/4885 |
| US-20060040963-A1 | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes | DPP4, DPP3, DPP7 | PPARA 484/4885PPARG 560/4885CTSS 1145/4885 |
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | UTS2R, ADORA3, P2RX7 | PPARA 738/4885PPARG 798/4885CTSS 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.